| Literature DB >> 32316137 |
Taremekedzwa Allan Sanyanga1, Özlem Tastan Bishop1.
Abstract
Human carbonic anhydrase 8 (CA-VIII) is an acatalytic isoform of the α -CA family. Though the protein cannot hydrate CO2, CA-VIII is essential for calcium (Ca2+) homeostasis within the body, and achieves this by allosterically inhibiting the binding of inositol 1,4,5-triphosphate (IP3) to the IP3 receptor type 1 (ITPR1) protein. However, the mechanism of interaction of CA-VIII to ITPR1 is not well understood. In addition, functional defects to CA-VIII due to non-synonymous single nucleotide polymorphisms (nsSNVs) result in Ca2+ dysregulation and the development of the phenotypes such as cerebellar ataxia, mental retardation and disequilibrium syndrome 3 (CAMRQ3). The pathogenesis of CAMRQ3 is also not well understood. The structure and function of CA-VIII was characterised, and pathogenesis of CAMRQ3 investigated. Structural and functional characterisation of CA-VIII was conducted through SiteMap and CPORT to identify potential binding site residues. The effects of four pathogenic nsSNVs, S100A, S100P, G162R and R237Q, and two benign S100L and E109D variants on CA-VIII structure and function was then investigated using molecular dynamics (MD) simulations, dynamic cross correlation (DCC) and dynamic residue network (DRN) analysis. SiteMap and CPORT analyses identified 38 unique CA-VIII residues that could potentially bind to ITPR1. MD analysis revealed less conformational sampling within the variant proteins and highlighted potential increases to variant protein rigidity. Dynamic cross correlation (DCC) showed that wild-type (WT) protein residue motion is predominately anti-correlated, with variant proteins showing no correlation to greater residue correlation. DRN revealed variant-associated increases to the accessibility of the N-terminal binding site residues, which could have implications for associations with ITPR1, and further highlighted differences to the mechanism of benign and pathogenic variants. SNV presence is associated with a reduction to the usage of Trp37 in all variants, which has implications for CA-VIII stability. The differences to variant mechanisms can be further investigated to understand pathogenesis of CAMRQ3, enhancing precision medicine-related studies into CA-VIII.Entities:
Keywords: MD-TASK; carbonic anhydrase VIII; dynamic cross correlation; dynamic residue network analysis; single nucleotide variation
Mesh:
Substances:
Year: 2020 PMID: 32316137 PMCID: PMC7215520 DOI: 10.3390/ijms21082764
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
The rs IDs, associated residue-variant substitutions and predicted variant consequences of the identified -carbonic anhydrase VIII single nucleotide variants (SNVs). Clinical significance data obtained from Clinvar. VAPOR was used to conduct I-Mutant and MUpro predictions.
| SNV | ||||||
|---|---|---|---|---|---|---|
| S100A | S100L | S100P | E109D | G162R | R237Q | |
|
| rs267606695 | rs149391728 | rs267606695 | rs7464181 | rs1421833180 | rs387906598 |
|
| 0.01 | <0.01 | <0.01 | 0.50 | <0.01 | <0.01 |
|
| −0.66 | −0.31 | −0.27 | −0.16 | −0.84 | −0.58 |
|
| −1.23 | −0.17 | −1.39 | −0.41 | −0.54 | −1.05 |
|
| Decrease | Decrease | Decrease | Decrease | Decrease | Decrease |
|
| Pathogenic | Benign | Pathogenic | Benign | Pathogenic | Pathogenic |
|
| −1.374 | −1.381 | −1.41 | −1.436 | −1.357 | −1.393 |
Figure 13-dimensional image of carbonic anhydrase VIII (CA-VIII) showing the SNV location, predicted binding site residues and location of each motif. Orange: S100A, S100L and S100P; Green: E109D; Purple: G162R; Magenta: R237Q. Spheres represent the binding site residues identified by SiteMap and CPORT, Green: Gly26, Val27, Glu28, Trp29, Gly30, Tyr31, Glu32, Glu33, Gly34, Val35, Glu36, Leu39, Val40, Ala44; Blue: Leu93, Lys94, Glu111, Tyr113, Arg116, Ser147, Gly151, Ile153, Asp214, Ile224, Arg237, Tyr238; Red: Thr255, His256, Leu262, Val263, Glu264, Gly265, Ile269, Phe274, Pro276, Gln278, Phe289, Gln290.
Figure 2-carbon RMSD and Rg distribution of the WT and variant proteins using the kernel density estimation. (A) RMSD; (B) Rg. The mean RMSD and Rg of the WT and variant proteins is presented as the dashed lines on each plot, and the colour of the dashed line is representative of the mean of the same coloured plot. The x-axis represents the sampled conformation RMSDs, and the y-axis peaks represent the RMSDs of the most sampled conformations.
Mean RMSD and Rg of the protein plots in Figure 2, and average percentage differences from the WT protein.
| Protein | Metric Mean | % Difference (WT – Variant) |
|---|---|---|
|
| ||
| WT | 2.507 | 0.00 |
| S100A | 2.465 | 1.68 |
| S100L | 2.002 | 20.14 |
| S100P | 2.251 | 10.21 |
| E109D | 2.222 | 11.37 |
| G162R | 2.862 | −14.16 |
| R237Q | 2.248 | 10.33 |
|
| ||
| WT | 18.120 | 0.00 |
| S100A | 17.961 | 0.88 |
| S100L | 17.926 | 1.07 |
| S100P | 18.024 | 0.53 |
| E109D | 17.865 | 1.41 |
| G162R | 18.113 | 0.04 |
| R237Q | 17.944 | 0.97 |
Figure 3CA-VIII DCC analysis showing protein residue correlation comparison between the WT and proteins. The x-axis and y-axis represent protein residues. A value of −1 indicates that residue movement is anti-correlated, 0 highlights no movement correlation and a value of 1 represents correlated residue movement.
Figure 4RMSF (WT − variant) comparison of WT and variant proteins. Respective CA-VIII secondary structure is shown as colour coded bars at the bottom of the plot. Red: -helix; Blue: -sheet.
Variant residues showing changes to L and BC in Figure S4. SNV positions are underlined, italicised and highlighted in bold red. Residues located within the CA-VIII binding site are underlined and highlighted in bold blue. Residues potentially important to CA-VIII stability are underlined and highlighted in bold orange. Overlapping potential protein-protein interaction and important structural residues are underlined and highlighted in bold green.
| Variant Protein | Dynamic Residue Network | |
|---|---|---|
| Residue Accessibility Increase (Positive | Residue Communication Reduction (Positive | |
| S100A | Glu23 Glu24 Glu25 | |
| S100L | Glu23 Glu25 | |
| S100P | Glu23 Glu24 Glu25 | |
| E109D | Glu23 Glu24 Glu25 | |
| G162R | Glu23 Glu24 Glu25 | |
| R237Q | Glu23 Glu24 Glu25 | |
|
|
| |
| S100A | Glu23 | |
| S100L | ||
| S100P | ||
| E109D | Glu25 | |
| G162R | Val157 Ala260 Leu262 | |
| R237Q | ||
Figure 5Non normalised average BC of the WT and variant protein residues during MD simulation.